Bioactive Human Alzheimer Brain Soluble Aβ: Pathophysiology and Therapeutic Opportunities

Overview

Journal Mol Psychiatry

Specialties Molecular Biology
Psychiatry

Date 2022 Apr 28

PMID 35484241

Authors

Shaomin Li

Andrew M Stern

Affiliations

Soon will be listed here.

Abstract

The accumulation of amyloid-β protein (Aβ) plays an early role in the pathogenesis of Alzheimer's disease (AD). The precise mechanism of how Aβ accumulation leads to synaptic dysfunction and cognitive impairment remains unclear but is likely due to small soluble oligomers of Aβ (oAβ). Most studies have used chemical synthetic or cell-secreted Aβ oligomers to study their pathogenic mechanisms, but the Aβ derived from human AD brain tissue is less well characterized. Here we review updated knowledge on the extraction and characterization of bioactive human AD brain oAβ and the mechanisms by which they cause hippocampal synaptic dysfunction. Human AD brain-derived oAβ can impair hippocampal long-term potentiation (LTP) and enhance long-term depression (LTD). Many studies suggest that oAβ may directly disrupt neuronal NMDA receptors, AMPA receptors and metabotropic glutamate receptors (mGluRs). oAβ also impairs astrocytic synaptic functions, including glutamate uptake, D-serine release, and NMDA receptor function. We also discuss oAβ-induced neuronal hyperexcitation. These results may suggest a multi-target approach for the treatment of AD, including both oAβ neutralization and reversal of glutamate-mediated excitotoxicity.

Citing Articles

Microglial Lyzl4 Facilitates β-Amyloid Clearance in Alzheimer's Disease.

Pan J, Zhong J, Geng J, Oberhauser J, Shi S, Wan J Adv Sci (Weinh). 2024; 12(2):e2412184.

PMID: 39555667 PMC: 11727385. DOI: 10.1002/advs.202412184.

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L Signal Transduct Target Ther. 2024; 9(1):211.

PMID: 39174535 PMC: 11344989. DOI: 10.1038/s41392-024-01911-3.

Mechanobiological insight into brain diseases based on mechanosensitive channels: Common mechanisms and clinical potential.

Li B, Zhao A, Tian T, Yang X CNS Neurosci Ther. 2024; 30(6):e14809.

PMID: 38923822 PMC: 11197048. DOI: 10.1111/cns.14809.

Rapidly reversible persistent long-term potentiation inhibition by patient-derived brain tau and amyloid ß proteins.

Ondrejcak T, Klyubin I, Hu N, Yang Y, Zhang Q, Rodriguez B Philos Trans R Soc Lond B Biol Sci. 2024; 379(1906):20230234.

PMID: 38853565 PMC: 11343230. DOI: 10.1098/rstb.2023.0234.

De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor.

Xu Y, Song R, Perszyk R, Chen W, Kim S, Park K Cell Mol Life Sci. 2024; 81(1):153.

PMID: 38538865 PMC: 10973091. DOI: 10.1007/s00018-023-05069-z.

References

Masters C, Bateman R, Blennow K, Rowe C, Sperling R, Cummings J . Alzheimer's disease. Nat Rev Dis Primers. 2016; 1:15056. DOI: 10.1038/nrdp.2015.56. View

Spires-Jones T, Hyman B . The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron. 2014; 82(4):756-71. PMC: 4135182. DOI: 10.1016/j.neuron.2014.05.004. View

Lue L, Kuo Y, Roher A, Brachova L, Shen Y, Sue L . Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999; 155(3):853-62. PMC: 1866907. DOI: 10.1016/s0002-9440(10)65184-x. View

McLean C, Cherny R, Fraser F, Fuller S, Smith M, Beyreuther K . Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999; 46(6):860-6. DOI: 10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m. View

Oddo S, Caccamo A, Tran L, Lambert M, Glabe C, Klein W . Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem. 2005; 281(3):1599-604. DOI: 10.1074/jbc.M507892200. View

Balducci C, Tonini R, Zianni E, Nazzaro C, Fiordaliso F, Salio M . Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in AβPP23 transgenic mice. J Alzheimers Dis. 2011; 21(4):1367-81. DOI: 10.3233/jad-2010-100675. View

Muller-Schiffmann A, Herring A, Abdel-Hafiz L, Chepkova A, Schable S, Wedel D . Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity. Brain. 2015; 139(Pt 2):509-25. DOI: 10.1093/brain/awv355. View

Li S, Selkoe D . A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain. J Neurochem. 2020; 154(6):583-597. PMC: 7487043. DOI: 10.1111/jnc.15007. View

Shankar G, Li S, Mehta T, Garcia-Munoz A, Shepardson N, Smith I . Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008; 14(8):837-42. PMC: 2772133. DOI: 10.1038/nm1782. View

10.

Walsh D, Klyubin I, Fadeeva J, Cullen W, Anwyl R, Wolfe M . Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416(6880):535-9. DOI: 10.1038/416535a. View

11.

Klyubin I, Walsh D, Lemere C, Cullen W, Shankar G, Betts V . Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005; 11(5):556-61. DOI: 10.1038/nm1234. View

12.

Li S, Jin M, Liu L, Dang Y, Ostaszewski B, Selkoe D . Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease. Acta Neuropathol Commun. 2018; 6(1):121. PMC: 6225562. DOI: 10.1186/s40478-018-0626-x. View

13.

Carrera I, Etcheverria I, Fernandez-Novoa L, Lombardi V, Lakshmana M, Cacabelos R . A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer's disease. Biomed Res Int. 2015; 2015:807146. PMC: 4339718. DOI: 10.1155/2015/807146. View

14.

Esang M, Gupta M . Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future. Cureus. 2021; 13(8):e17591. PMC: 8483432. DOI: 10.7759/cureus.17591. View

15.

Rabinovici G . Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab. N Engl J Med. 2021; 385(9):771-774. DOI: 10.1056/NEJMp2111320. View

16.

Swanson C, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai R . A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021; 13(1):80. PMC: 8053280. DOI: 10.1186/s13195-021-00813-8. View

17.

Mintun M, Lo A, Evans C, Wessels A, Ardayfio P, Andersen S . Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021; 384(18):1691-1704. DOI: 10.1056/NEJMoa2100708. View

18.

Kollmer M, Close W, Funk L, Rasmussen J, Bsoul A, Schierhorn A . Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer's brain tissue. Nat Commun. 2019; 10(1):4760. PMC: 6820800. DOI: 10.1038/s41467-019-12683-8. View

19.

Yang Y, Arseni D, Zhang W, Huang M, Lovestam S, Schweighauser M . Cryo-EM structures of amyloid-β 42 filaments from human brains. Science. 2022; 375(6577):167-172. PMC: 7612234. DOI: 10.1126/science.abm7285. View

20.

Esparza T, Zhao H, Cirrito J, Cairns N, Bateman R, Holtzman D . Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2012; 73(1):104-19. PMC: 3563737. DOI: 10.1002/ana.23748. View